



Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

You are about to purchase a product that is not simple and may be difficult to understand.

Product

| | |
|------------------------------------|--|
| Product name | Capital Protection Certificate on STOXX® Europe 600 Health Care EUR Price Index (Price return index) |
| Product identifiers | ISIN: AT0000A25145 Series number: 31926 German Wertpapierkennnummer: RC0SV1 |
| Manufacturer of the Product | Raiffeisen Centrobank AG (Issuer)/ www.rcb.at/ call +43/1/515 20-484 for more information |
| Competent Authority | Financial Market Authority (FMA), Austria |
| Date and time of production | 13 September 2022 13:01 Vienna local time |

1. What is this product?

Type This product is issued under Austrian law and entitles the respective holder to receive any amount due from us as the Issuer (bearer form).

Objectives (Terms that appear in **bold** in this section are described in more detail in the table(s) below.) The product is designed to provide a return in the form of a cash payment on the **maturity date**. The amount of this payment will depend on the performance of the **underlying**. The product has a fixed term and will terminate on the **maturity date**. On termination of the product on the **maturity date** you will receive a cash payment directly linked to the performance of the **underlying**. The cash payment will equal (i) the **product notional amount** multiplied by (ii) (A) the **final reference level** divided by (B) EUR 691.67. However, if this cash payment exceeds CZK 1,150, you will only receive CZK 1,150 (the maximum payment) and if it is less than CZK 1,050, you will receive CZK 1,050 (the minimum payment).

Under the product terms, certain dates specified below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the product issuer may terminate the product early. These events are specified in the product terms and principally relate to the **underlying**, the product and the product issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.

| | | | |
|--------------------------------|--|-------------------------------|---|
| Underlying | STOXX® Europe 600 Health Care EUR Price Index (Price return index) (ISIN: EU0009658723; Bloomberg: SXDP Index; RIC: .SXDP) | Strike level | EUR 726.2535 (105.00% of the initial reference level) |
| Underlying market | Equity | Cap | EUR 795.4205 (115.00% of the initial reference level) |
| Product notional amount | CZK 1,000 | FX rate | 1 (Quanto) |
| Product currency | Czech Koruna (CZK) | Reference level | The closing level of the underlying as per the reference source |
| Underlying currency | Euro (EUR) | Reference source | STOXX Limited |
| Issue date | 28 December 2018 | Final reference level | The reference level on the final valuation date |
| Initial reference level | EUR 691.67 | Initial valuation date | 27 December 2018 |
| Protection amount | CZK 1,050 | Final valuation date | 22 December 2023 |
| Participation rate | 100.00% | Maturity date / term | 28 December 2023 |

Intended retail client The product is intended for private clients, professional clients and qualified counterparties who pursue the objective of general asset accumulation/asset optimization and have a short-term investment horizon. This product is for customers with basic knowledge and/or experience with financial products. The investor can bear no or only small losses on the capital invested and is willing to accept a level of risk to achieve potential returns that is consistent with the summary risk indicator shown below.

2. What are the risks and what could I get in return?

Risk indicator



← Lower risk Higher risk →



The risk indicator assumes you keep the product for 1 year and 3 months. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 3 out of 7, which is a medium-low risk class. This rates the potential losses from future performance at a low level, and poor market conditions are unlikely to impact our capacity to pay you.

Be aware of currency risk: If the currency of your account is different to the currency of this product, you will be exposed to the risk of suffering a loss as a result of the conversion of the currency of the product into the account currency. This risk is not considered in the indicator shown above.

You are entitled to the return of at least the protection amount. As for the amounts of repayments, they depend on the future performance of the market and remain uncertain. However, this protection against forward market performance does not apply before maturity or in the event of immediate termination by the issuer.

If we are not able to pay you what is owed, you could lose your entire investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

Performance scenarios Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.

| <i>Investment: CZK 300,000</i> | | | |
|--------------------------------|--|-----------------------|---|
| <i>Scenarios</i> | | <i>1 year</i> | <i>1 year and 3 months (Recommended holding period)</i> |
| Stress scenario | What you might get back after costs | CZK 289,185.37 | CZK 301,032.11 |
| | Average return each year | -3.60% | 0.27% |
| Unfavourable scenario | What you might get back after costs | CZK 317,135.15 | CZK 329,701.83 |
| | Average return each year | 5.71% | 7.57% |
| Moderate scenario | What you might get back after costs | CZK 318,176.57 | CZK 329,701.83 |
| | Average return each year | 6.06% | 7.57% |
| Favourable scenario | What you might get back after costs | CZK 318,176.57 | CZK 329,701.83 |
| | Average return each year | 6.06% | 7.57% |

This table shows the money you could get back over the next year and 3 months under different scenarios, assuming that you invest CZK 300,000.

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products. **The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the product.** The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you. In addition, you should note that the results shown for the intermediate holding period do not reflect estimates of the product's future value. You should therefore not base your investment decision on the results shown for this interim holding period.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

3. What happens if Raiffeisen Centrobank AG is unable to pay out?

You are exposed to the risk that the issuer might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or in case of certain resolution measures ordered by the respective resolution authority in case of a crisis of the issuer. In that case the resolution authority has a wide-ranging power to take actions, e.g. to reduce the claims of the investors up to zero, to terminate or convert the products into shares of the issuer, to suspend rights of the issuer ("Bail-In"). This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not a deposit and as such is not covered by any deposit protection scheme.

4. What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for two different holding periods. They include potential early exit penalties. The figures assume you invest CZK 300,000. The figures are estimates and may change in the future.

Costs over time

| <i>Investment: CZK 300,000</i> | | |
|--|------------------------------------|--|
| <i>Scenarios</i> | <i>If you cash in after 1 year</i> | <i>If you cash in at the end of the recommended holding period</i> |
| Total costs | CZK 8,600.92 | CZK 4,349.37 |
| Impact on return (RIY) per year | 2.99828% | 1.22044% |

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- The meaning of the different cost categories.

The table shows the impact on return per year.

| | | | |
|----------------------|--------------------|----------|---|
| One-off costs | <i>Entry costs</i> | 1.22044% | The impact of the costs already included in the price. |
| | <i>Exit costs</i> | 0.00% | The impact of the costs of exiting your investment when it matures. |

5. How long should I hold it and can I take money out early?

Recommended holding period: 1 year and 3 months

The product aims to provide you with the return described under “1. What is this product?” above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 28 December 2023 (maturity).

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. No fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

| | | | |
|-------------------------------|----------------|------------------------|------------|
| Exchange listing | Not applicable | Price quotation | Percentage |
| Smallest tradable unit | CZK 1,000.00 | | |

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

6. How can I complain?

Any complaint about the product or the conduct of the Issuer or the person advising on, or selling, the product can be submitted to Raiffeisen Centробank AG under the following address: Compliance Office, Raiffeisen Centробank AG, Am Stadtpark 9, 1030 Vienna or using the contact form on www.rcb.at/beschwerdemanagement or via email to complaints@rcb.at.

7. Other relevant information

Any additional documents in relation to the product are published on our website (www.rcb.at), including the final terms and the base prospectus as required by § 10 para. 3 no. 3 first case of the Austrian Kapitalmarktgesetz (Austrian Capital Market Act).

This Key Information Document is for submission in Czech Republic.